1101 related articles for article (PubMed ID: 20106720)
21. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
22. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
[TBL] [Abstract][Full Text] [Related]
23. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
[TBL] [Abstract][Full Text] [Related]
24. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Bajetta E; Pietrantonio F; Buzzoni R; Ferrario E; Valvo F; Mariani L; Dotti KF; Biondani P; Formisano B; Gevorgyan A; Grassi P; Di Bartolomeo M
Am J Clin Oncol; 2014 Dec; 37(6):545-9. PubMed ID: 23428953
[TBL] [Abstract][Full Text] [Related]
25. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Yamazaki T; Gunderson AJ; Gilchrist M; Whiteford M; Kiely MX; Hayman A; O'Brien D; Ahmad R; Manchio JV; Fox N; McCarty K; Phillips M; Brosnan E; Vaccaro G; Li R; Simon M; Bernstein E; McCormick M; Yamasaki L; Wu Y; Drokin A; Carnahan T; To Y; Redmond WL; Lee B; Louie J; Hansen E; Solhjem MC; Cramer J; Urba WJ; Gough MJ; Crittenden MR; Young KH
Lancet Oncol; 2022 Sep; 23(9):1189-1200. PubMed ID: 35952709
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
[TBL] [Abstract][Full Text] [Related]
27. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
[TBL] [Abstract][Full Text] [Related]
28. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
30. Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
Engelen SM; Maas M; Lahaye MJ; Leijtens JW; van Berlo CL; Jansen RL; Breukink SO; Dejong CH; van de Velde CJ; Beets-Tan RG; Beets GL
Eur J Cancer; 2013 Jul; 49(10):2311-20. PubMed ID: 23571146
[TBL] [Abstract][Full Text] [Related]
31. Role of neoadjuvant treatment in cT3N0M0 rectal cancer.
Pasetto LM; Friso ML; Pucciarelli S; Basso U; Rugge M; Sinigaglia G; Rossi E; Compostella A; Toppan P; Agostini M; Monfardini S
Anticancer Res; 2008; 28(6B):4129-35. PubMed ID: 19192672
[TBL] [Abstract][Full Text] [Related]
32. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
33. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
[TBL] [Abstract][Full Text] [Related]
34. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
[TBL] [Abstract][Full Text] [Related]
35. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
36. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
Gérard JP; Azria D; Gourgou-Bourgade S; Martel-Lafay I; Hennequin C; Etienne PL; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah JF; Mahé MA; Bécouarn Y; Dupuis O; Lledo G; Seitz JF; Bedenne L; Juzyna B; Conroy T
J Clin Oncol; 2012 Dec; 30(36):4558-65. PubMed ID: 23109696
[TBL] [Abstract][Full Text] [Related]
37. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
[TBL] [Abstract][Full Text] [Related]
38. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
Hospers GA; Punt CJ; Tesselaar ME; Cats A; Havenga K; Leer JW; Marijnen CA; Jansen EP; Van Krieken HH; Wiggers T; Van de Velde CJ; Mulder NH
Ann Surg Oncol; 2007 Oct; 14(10):2773-9. PubMed ID: 17653805
[TBL] [Abstract][Full Text] [Related]
39. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Konishi T; Shinozaki E; Murofushi K; Taguchi S; Fukunaga Y; Nagayama S; Fujimoto Y; Akiyoshi T; Nagasaki T; Suenaga M; Chino A; Kawachi H; Yamamoto N; Ishikawa Y; Oguchi M; Ishizuka N; Ueno M; Yamaguchi K
Ann Surg Oncol; 2019 Aug; 26(8):2507-2513. PubMed ID: 30963400
[TBL] [Abstract][Full Text] [Related]
40. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Fokas E; Conradi L; Weiss C; Sprenger T; Middel P; Rau T; Dellas K; Kitz J; Rödel F; Sauer R; Rüschoff J; Beissbarth T; Arnold D; Ghadimi BM; Rödel C; Liersch T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):992-9. PubMed ID: 24210078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
